A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine ...

A phase 2 clinical study (NCT03974022)found that sunvozertinib (Zegfrovy) was efficacious in 2 different doses, but ...

Botensilimab and balstilimab showed promising survival outcomes in advanced solid tumors, with a median OS of 17.2 months and 39% 24-month survival. The study reported a 17% overall response rate and ...

This is the second time within months that Roche’s potential first-in-class TIGIT product has failed a Phase III study.

A new study has found that receiving messenger RNA-based COVID-19 vaccines such as those from Pfizer (NYSE:PFE)/BioNTech ...

To further back their findings, University of Florida researchers replicated the effect in mice. They paired immunotherapy ...

Race and economic disparities significantly affect lung cancer treatment and outcomes with worse outcomes seen in Black and ...

Learn how combining recent insights from immunotherapy and COVID-19 vaccines could pave the way for a universal cancer ...

However, the research team head cautioned that it is still too early to recommend the mRNA COVID-19 vaccine as a standard ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...

Cancer patients receiving a certain type of immunotherapy were twice as likely to be alive after three years if they received a COVID-19 mRNA vaccine within 100 days of beginning cancer treatment, new ...